The Independent Data Monitoring Committee recommended transitioning patients in the placebo arm to garetosmab as soon as possible. Topline data were announced from a phase 3 trial evaluating ...

BELLMAWR, New Jersey (WPVI) -- A young South Jersey boy has one wish for his birthday this year, and that is to help raise money for those living with a rare disease. Nine-year-old AJ Gonzales of ...

FOP is a disease in which muscles, tendons and ligaments are progressively replaced by bone, leading to eventual incapacitation Garetosmab is the first and only treatment to demonstrate a dramatic ...

FRANKLIN COUNTY, Va. – Tyler is a 14 year-old boy who lives in Franklin County and attends Benjamin Franklin Middle School. Tyler has the rare terminal disease Fibrodysplasia Ossificans Progressiva ...

PARIS, FRANCE, 19 December 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the pivotal Phase II FALKON trial did not meet its primary endpoint of reducing new heterotopic ossification ...

FOP is an ultra-rare disease that causes permanent and continuous bone formation in soft and connective tissues like muscles, tendons and ligaments, also known as heterotopic ossification or HO. 1 As ...

Fibrodysplasia ossificans progressiva (FOP) is a rare and life-threatening genetic disease caused by gain-of-function mutations in the ALK2 gene, which encodes activin receptor-like kinase 2.

BRISBANE, Calif.--(BUSINESS WIRE)--āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of severe bone and connective tissue disorders, today ...

Ipsen, a global biopharmaceutical company with a focus on bringing transformative medicines to patients, announced that the pivotal phase II FALKON trial did not meet its primary endpoint of reducing ...